On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Annemiek Vermeeren, Stefan Jongen, Patricia Murphy, Margaret Moline, Gleb Filippov, Kate Pinner, Carlos Perdomo, Ishani Landry, Oneeb Majid, Anita C M Van Oers, Cees J Van Leeuwen, Johannes G Ramaekers, Eric F P M Vuurman, Annemiek Vermeeren, Stefan Jongen, Patricia Murphy, Margaret Moline, Gleb Filippov, Kate Pinner, Carlos Perdomo, Ishani Landry, Oneeb Majid, Anita C M Van Oers, Cees J Van Leeuwen, Johannes G Ramaekers, Eric F P M Vuurman

Abstract

Study objectives: To assess potential effects of lemborexant on next-morning driving performance in adult and elderly healthy volunteers.

Methods: Randomized, double-blind, double-dummy, placebo and active-controlled, four period incomplete crossover study in 48 healthy volunteers (22 females), 23-78 years old. Participants were treated at bedtime for eight consecutive nights with two of three dose levels of lemborexant (2.5, 5, or 10 mg), zopiclone 7.5 mg (on the first and last night with placebo on intervening nights), or placebo. Driving performance was assessed in the morning on days 2 and 9 using a standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug-placebo differences in SDLP >2.4 cm were considered to reflect clinically meaningful driving impairment.

Results: Mean drug-placebo differences in SDLP following lemborexant 2.5, 5, and 10 mg on days 2 and 9 were 0.74 cm or less. The upper bound of the 95% confidence intervals (CIs) for lemborexant treatment groups were all below 2.4 cm and the 95% CIs included zero, indicating that the effects were neither clinically meaningful nor statistically significant. Symmetry analysis further supported the lack of clinically meaningful impairment with lemborexant.

Conclusions: When assessed starting ~9 h after lemborexant administration at bedtime the previous night, there was no statistically significant or clinically meaningful effect on driving performance in healthy adults and elderly, as assessed by either mean differences in SDLP relative to placebo or symmetry analysis. In this study, lemborexant at doses up to 10 mg was well-tolerated.

Clinical trial registration: clinicaltrials.gov, NCT02583451. https://ichgcp.net/clinical-trials-registry/NCT02583451.

Keywords: adults; driving; elderly; hypnotics; lemborexant; orexin antagonist; plasma concentrations; zopiclone.

© Sleep Research Society 2018. Published by Oxford University Press [on behalf of the Sleep Research Society].

Figures

Figure 1.
Figure 1.
Highway driving test. (A) Subjects drive a specially instrumented vehicle for about 1 h over a 100 km primary highway circuit, accompanied by a licensed driving instructor having access to dual controls. The subjects’ task is to drive with a steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 km/h. (B) A camera on top of the car continuously registers the lateral position of the car on the road with respect to the left lane delineation. (C) The standard deviation of lateral position (SDLP in cm) is an index of road tracking error or “weaving.” SDLP scores increase compared with placebo after the use of many sedating drugs including low doses of alcohol. SDLP, standard deviation of lateral position.
Figure 2.
Figure 2.
Individual standard deviation of lateral position (SDLP, in cm) differences from placebo, mean and 95% confidence interval by treatment and day, following bedtime administration of lemborexant 2.5, 5, and 10 mg single dose (day 2, n = 32) and repeated doses (day 9, n = 32), and single doses of zopiclone 7.5 mg (days 2 and 9, n = 48). N = 28 on day 2, N = 27 on day 9. Horizontal dashed lines indicate thresholds for impairment (>2.4 cm) and improvement (<−2.4 cm). LEM2.5, lemborexant 2.5 mg; LEM5, lemborexant 5 mg; LEM10, lemborexant 10 mg; SDLP, standard deviation of lateral position; ZOP, zopiclone 7.5 mg.

References

    1. Murphy PJ, et al. . Concentration-response modeling of ECG data from early-phase clinical studies as an alternative clinical and regulatory approach to assessing qt risk—experience from the development program of lemborexant. J Clin Pharmacol. 2017;57(1):96–104.
    1. Beuckmann CT, et al. . In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362(2):287–295.
    1. Yoshida Y, et al. . Discovery of (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist. J Med Chem. 2015;58(11):4648–4664.
    1. Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci. 2014;15(11):719–731.
    1. de Lecea L, et al. . Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5:16.
    1. Fulcher BD, et al. . A physiologically based model of orexinergic stabilization of sleep and wake. PLoS One. 2014;9(3):e91982.
    1. Scammell TE, et al. . Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243–266.
    1. Michelson D, et al. . Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–471.
    1. Tang S, et al. . Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61.
    1. Nofzinger EA, et al. . Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry. 2004;161(11): 2126–2128.
    1. Pastino G, et al. . Pharmacokintetics of lemborexant: relationships to efficacy and safety. In: Poster presented at: SLEEP 2015, the 29th Annual Meeting of the Associated Professional Sleep Societies, June 5–10, 2015; Seattle.
    1. Food and Drug Administration. Evaluating Drug Effects on the Ability to Operate a Motor Vehicle, Guidance for Industry 2017. Accessed October 2, 2017.
    1. Dassanayake T, et al. . Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011;34(2):125–156.
    1. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297–328.
    1. Murphy P, et al. . Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13(11):1289–1299.
    1. O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol. 1984;18(Suppl 1):121S–129S.
    1. Ramaekers JG. Drugs and driving research in medicinal drug development. Trends Pharmacol Sci. 2017;38(4): 319–321.
    1. Verster JC, et al. . Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med. 2011;4:359–371.
    1. Louwerens JW, et al. . The relationship between drivers’ blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: International Congress on Alcohol, Drugs and Traffic Safety Amsterdam: Exerpta Medica; 1987:183–186.
    1. Jongen S, et al. . A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L. Psychopharmacology (Berl). 2017;234(5):837–844.
    1. Laska E, et al. . A maximally selected test of symmetry about zero. Stat Med. 2012;31(26):3178–3191.
    1. Vermeeren A, et al. . Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use. Sleep. 2014;37(3):489–496.
    1. Vermeeren A, et al. . On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015;38(11):1803–1813.
    1. Vermeeren A, et al. . On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology (Berl). 2016;233(18):3341–3351.
    1. Verster JC, et al. . Lapses of attention as outcome measure of the on-the-road driving test. Psychopharmacology (Berl). 2014;231(1):283–292.
    1. Verster JC, et al. . Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf. 2011;6(4):209–218.
    1. Maich KHG, et al. . Psychometric properties of the consensus sleep diary in those with insomnia disorder. Behav Sleep Med. 2018;16(2):117–134.
    1. Leufkens TR, et al. . Zopiclone’s residual effects on actual driving performance in a standardized test: a pooled analysis of age and sex effects in 4 placebo-controlled studies. Clin Ther. 2014;36(1):141–150.
    1. Ramaekers JG, et al. . Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011;215(2):321–332.
    1. Senn S, et al. . An incomplete blocks cross-over in asthma: a case study in collaboration. In: Vollmar J, Hothorn LJ, eds. Biometrics in the Pharmaceutical Industry 7: Cross-Over Clinical Trials. Stuttgart: Gustav Fischer Verlag; 1997: 3–26.
    1. Verster JC, et al. . The prevalence and nature of stopped on-the-road driving tests and the relationship with objective performance impairment. Accid Anal Prev. 2012;45:498–506.
    1. Verster JC, et al. . Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. Sleep Med Rev. 2013;17(2):153–159.
    1. Leufkens TR, et al. . Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study. Psychopharmacology (Berl). 2014;231(14):2785–2798.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner